<DOC>
	<DOCNO>NCT00735332</DOCNO>
	<brief_summary>The objective study assess efficacy safety TLN-232 use treat patient metastatic melanoma recur/progress receive first line systemic therapy .</brief_summary>
	<brief_title>Efficacy Study TLN-232 Patients With Recurring Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirm stage IV ( M1a , M1b , M1c ) unresectable metastatic melanoma ( cutaneous , mucosal acral lentiginous ) First progression treatment one first line systemic therapy metastatic melanoma ( immunotherapy target therapy chemotherapy combination ) Measurable recurrent/progressive disease radiological scan ≤ 21 day prior Day 1 , Cycle 1 Age ≥ 18 year ECOG ≤ 2 Normal organ marrow function define : Leukocytes ≥2.5 x 109/L Absolute neutrophil count ≥1.5 x 109/L Platelets ≥100 x 109/L Hemoglobin ≥100 g/L ( 10g/dL ) Total bilirubin ≤1.5 X institutional ULN AST ( SGOT ) /ALT ( SGPT ) ≤2.5 X institutional ULN Creatinine ≤1.5 X institutional ULN Patients life expectancy ≤ 16 week Patients ocular melanoma Patients symptomatic and/or unstable brain metastasis last 3 month ( 90 day ) prior Day 1 , Cycle 1 Patients history allergic reaction hypersensitivity somatostatin analogue Patients document history HIV , active hepatitis B C infection Female patient pregnant lactate Patients receive hormonal therapy ( exception hormone replacement therapy hormonal contraceptive ) , systemic steroid , immunosuppressive therapy coumadin ( low molecular weight heparin permit ) Patients grade ≥2 peripheral neuropathy ( CTCAE criterion ) Patients proper central line establish</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Metastatic Melanoma</keyword>
	<keyword>Phase II</keyword>
	<keyword>Skin Cancer</keyword>
</DOC>